In this episode of NGBiLab, Jim Wilson speaks with co-founder and CTO Kris Rupay about a company that started in a garage during the pandemic and was originally founded to help restore confidence in air travel. What began as a UV disinfection robot for airplane aisles evolved into a potentially life-saving technology now being deployed in hospitals across North America.

The team at HygenX.AI have developed an autonomous AI-driven robotic UV disinfection technology that is designed to make healthcare spaces safer, faster, and cleaner. Their robot, RAY, can disinfect a patient room in minutes rather than hours, while generating a real-time digital map of exactly what has been treated.

Kris also talks about the challenges of pivoting from aviation to healthcare, the steep learning curve of building a medtech company without having a background in healthcare, and why he believes hospital-acquired infections are one of the most underreported public health crises in the world.

In the next episode of NGBideas Jim Wilson sits down with Gerald Prince who is Senior Director of GMP Manufacturing Gerald Prince at Bluerock Therapeutics. Gerald's professional journey has wound through some of North America's largest food, consumer goods, and pharmaceutical companies and ultimately landed him at MaRS Discovery District in Toronto. Gerald's story began in Stockton, California where his childhood home was unfortunately touched by gun violence but teachers and coaches believed in him before he believed in himself and their encouragement helped set Gerald on a career path defined by leadership, ambition and perseverence. His journey eventually brought him to Canada and the forefront of cell and gene therapy where he and his team are helping change the future of medicine. It is an inspiring story and we know you will enjoy learning about it.

Targa Biomedical is developing pharmacological solutions designed to improve the quality of cells, tissues, and organs for transplantation and regenerative medicine. Based in Montreal, Quebec, their technology has the potential to rescue damaged donor organs that would otherwise be discarded, making more transplants possible for patients in need.

In this episode, host Jim Wilson speaks with co-founder and CEO Shant Der Sarkissian about how a chance observation in the lab, combined with a conversation with a cardiac surgeon next door, became the foundation for a company seven years in the making. Shant walks through the science behind conditioning damaged organs outside the body and why Targa believes it is first to market with this specific approach.

Shant also reflects on the unique challenges of being an academic entrepreneur, and why he believes the confusion of having too many career options is actually a blessing in disguise.

SPEC Labs is a not-for-profit organization in Mississauga, Ontario that provides shared, ready-to-use wet lab space for life sciences startups in need of room to grow. Their all-inclusive model is designed to remove one of the biggest barriers facing Canadian biotech companies: access to affordable lab infrastructure.

In this episode, host Jim Wilson speaks with founder and CEO Doris Qamar about how a frustrating gap in the Canadian market sparked an idea that took years to bring to life. What started as a search for scalable lab space for a small biotech company became a 20,000 square foot facility in Sheridan Research Park, now open and welcoming its first clients.

Doris also makes a passionate case for why keeping innovation and intellectual property in Canada matters now more than ever.

Dr. Kullervo Hynynen is Vice President of Research and Innovation at Sunnybrook Health Sciences Centre in Toronto, Ontario, and a global leader in focused ultrasound technology. His decades of work have helped transform how the medical community approaches treatment for some of the most challenging neurological and oncological conditions.

Join host Jim Wilson as he speaks with Dr. Hynynen about his remarkable journey that began on a small farm in rural Finland and lead to one of the most significant breakthroughs in the history of neuroscience. What started as a rejected NIH grant proposal became the foundation for a technology that can now open the blood-brain barrier non-invasively, potentially unlocking treatment for conditions like Alzheimer's and brain cancer.

Kullervo also reflects on the personal losses that shaped his commitment to cancer research, and how a series of serendipitous career decisions, from Aberdeen to Arizona to Boston to Toronto, brought him to Sunnybrook.

This conversation covers the stubbornness required to push through years of failed experiments, the challenge of commercializing science in Canada, and why Kullervo believes the next frontier is a focused ultrasound helmet that patients could one day use at home.

Cove Neurosciences is a precision neuroscience company in Toronto, Ontario that is focused on translating complex brain data into meaningful insights. Their analytics software helps researchers and pharmaceutical companies better understand human brain function without requiring specialized data science expertise.

In this episode, host Jim Wilson speaks with co-founder and CEO Dr. Nardin Samuel about the company's unexpected beginnings inside a University of Toronto research lab. What started as a grant application to solve a data analysis problem became the foundation for a commercial software platform now targeting pharmaceutical companies and EEG device manufacturers.

Nardin also opens up about the unique challenge of balancing life as a practicing neurology resident with running a startup, and how the team grew early on through university internship programs.

This conversation covers the realities of the entrepreneurial rollercoaster, the mentorship that shaped Cove's early growth, and why Nardin believes that filtering signal from noise in brain data and in business is the key to staying focused on what matters most.

Innovation Factory in Hamilton, Ontario is one of 17 regional innovation centres across Ontario providing free advisory services, training, and mentorship to entrepreneurs at every stage - from idea to scale-up. With a particular strength in life sciences, roughly 35% of the 850+ companies Innovation Factory supports each year come from that sector, drawn in part by Hamilton's exceptional ecosystem of hospitals, universities, and research institutions.

In this episode, host Jim Wilson speaks with Shannon Graszat, Manager of Venture Growth at Innovation Factory, about how the organization helps founders turn ideas into products, access hospital and university networks, and tap into funding programs - all at no cost. Shannon discusses the Synapse Life Sciences Consortium, which brings together key institutional partners to support life sciences companies not just locally, but from across the province and country.

This conversation highlights why Hamilton has emerged as a hub for life sciences innovation in Canada, and how entrepreneurs anywhere in Ontario can access Innovation Factory's growing suite of resources - remotely or in person.

Skinopathy is a medical technology company in Toronto that is on a mission to provide accessible healthcare on demand. By integrating advanced artificial intelligence with smartphone technology, Skinopathy allows patients to screen for skin cancer and other conditions from home, bridging the gap between early detection and specialized medical intervention.

In this episode, host Jim Wilson speaks with co-founder and CEO Keith Loo about the company’s "accidental" beginnings during the COVID-19 pandemic. What started as a conversation between friends about the alarming rise in late-stage skin cancer became a life-saving tool now used globally. Keith discusses the technical challenge of building AI that works on all skin tones, navigating Canadian healthcare bureaucracy, and the emotional weight of building a company that helps patients "cancel their funerals."

This conversation explores the intersection of high-tech innovation and human-centric care, highlighting how a tool meant to be given away for free evolved into a clinically validated platform that outperforms traditional diagnostic standards.